REG - Spectral MD Holdings - Block Admission

Spectral MD HoldingsAnnouncement

07/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221107:nRSG1220Fa&default-theme=true

RNS Number : 1220F  Spectral MD Holdings, Ltd.  07 November 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Block Admission

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI and optical technology for
faster and more accurate treatment decisions in wound care, announces that a
block listing application ("Block Listing") has been made to the London Stock
Exchange for up to 2.0 million shares of common stock of US $0.001 ("Common
Stock") in the Company ("Shares") to be admitted to trading on AIM.

These Shares will be issued and allotted from time to time pursuant to the
exercise of employee options which have been issued pursuant to the Company's
2018 Long-Term Incentive Plan and have varying exercise prices from US $0.02
to US $0.53 per share.

The Block Listing has been filed to enable holders of the Company's options to
continue to voluntarily exercise them without the need for the issue of a
separate RNS and admissions filing each time this occurs.  The Company will
notify on a monthly basis when there are changes to the issued share capital
of the Company, and these monthly figures may be used by shareholders as the
denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company. The Company will also make announcements every
six months regarding the utilisation of the block admission in line with its
obligations under AIM Rule 29.  It is expected that the Block Listing will
become effective on or around November 8, 2022.

If and when issued, the Shares will rank pari passu in all respects with the
existing Common Stock of the Company.

As at the date of this announcement, the total number of Common Stock in the
Company is 136,249,564, with one voting right per Share. This figure may be
used by shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the issued share capital of the Company under the
Company's Certificate of Incorporation. No Common Stock is held in treasury.

 

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson                  Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Alice Woodings                                    +44 (0)7407 804 654

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSBLBDBSGGDGDD